Neuroprotective role of Noggin in spinal cord injury

作     者：Nadia Al-Sammarraie Mohammed Mahmood Swapan K.Ray Nadia Al-Sammarrraie;Mohammed Mahmood;Swapan K.Ray

作者机构：Department of PathologyMicrobiologyand ImmunologyUniversity of South Carolina School of MedicineColumbiaSCUSA 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2023年第18卷第3期

页      面：492-496页

核心收录：

学科分类：1002[医学-临床医学] 100210[医学-外科学(含：普外、骨外、泌尿外、胸心外、神外、整形、烧伤、野战外)] 10[医学] 

基　　金：supported by SCIRF-2020 PD-01 from the South Carolina Spinal Cord Injury Research Fund(Columbia SC USA)(to SKR) 

主　　题：apoptosis astrocyte differentiation axon myelination axon regeneration bone morphogenetic protein glial scar heterotrophic ossification neurogenesis neuropathic pain Noggin spinal cord injury 

摘      要：Spinal cord injury is one of the leading causes of morbidity and mortality among young adults in many countries including the United *** in the regeneration of neurons is one of the main obstacles that leave spinal cord injury patients with permanent paralysis in most *** research has found that preventing acute and subacute secondary cellular damages to the neurons and supporting glial cells can help slow the progression of spinal cord injury pathogenesis,in part by reactivating endogenous regenerative proteins including Noggin that are normally present during spinal cord *** is a complex protein and natural inhibitor of the multifunctional bone morphogenetic proteins,and its expression is high during spinal cord development and after induction of spinal cord *** this review article,we first discuss the change in expression of Noggin during pathogenesis in spinal cord ***,we discuss the current research knowledge about the neuroprotective role of Noggin in preclinical models of spinal cord ***,we explain the gap in the knowledge for the use of Noggin in the treatment of spinal cord *** results from extensive in vitro and in vivo research have revealed that the therapeutic efficacy of Noggin treatment remains debatable due to its neuroprotective effects observed only in early phases of spinal cord injury but little to no effect on altering pathogenesis and functional recovery observed in the chronic phase of spinal cord ***,clinical information regarding the role of Noggin in the alleviation of progression of pathogenesis,its therapeutic efficacy,bioavailability,and safety in human spinal cord injury is still lacking and therefore needs further investigation.